SERS-baserad sensor för detektion av låga nivåer av onkogena proteiner i biologiska prover

Diarienummer 2016-02082
Koordinator Karolinska Institutet - Dept of Laboratory Medicine, Clinical Research Center
Bidrag från Vinnova 1 532 642 kronor
Projektets löptid juli 2016 - juni 2018
Status Avslutat
Ansökningsomgång VINNMER Marie Curie Academy Outgoing 2016-03-16

Syfte och mål

A senor technology platform using a nanotechnology-based approach aiming at molecular detection of relevant biomedical markers in the medical field was to be developed in the form of SERS-based sensors for monitoring low levels of biomolecules. Feasibility of this platform towards future application was to be tested, involving also a risk analysis concerning biocompatibility. The project was also supposed to allow the VINMER fellow to gain experience towards a future career as group leader.

Resultat och förväntade effekter

The following key scientific milestones were achieved: i) Synthesis of nanoparticles for SERS and demonstration of the working principle. ii) Detailed biocompatibility study of the nanoparticles used for SERS, in particular concerning their interaction with cells. iii) Complementary high-throughput detection of biomolecules in clinical samples with fluorescence as comparative method. The VINMER fellow achieved important skills towards pursuing a careers as independent group leader.

Upplägg och genomförande

The project was developed to study a novel technology platform based on SERS with potential impact towards diagnosis in medicine. Thus work was implemented concerning the following aspects: i) achieving access to clinically relevant samples and benchmarking their detection with existing platforms (flow cytometry). ii) Development of nanoparticle materials for SERS-based detection. iii) Risk assessment in the form of detailed biocompatibility analysis of the nanoparticles used for SERS

Texten på denna sida har projektgruppen själv formulerat och innehållet är ej granskat av våra redaktörer.